Previous 10 | Next 10 |
FLORHAM PARK, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office...
Cellectar Biosciences (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has closed an underwritten public offering for gross proceeds of $20.0 million. According to the update, the offeri...
IZEA Worldwide (NASDAQ: IZEA ) +79% . More news on: IZEA Worldwide, Inc., Second Sight Medical Products, Inc., Immuron Limited, Stocks on the move, , Read more ...
Cellectar Biosciences (NASDAQ: CLRB ) has closed its public offerin g of ~14.6M common shares and accompanying Series H warrants to purchase ~8.7M shares at $1.2075. It also issued ~2.8M pre-funded warrants. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, , Stocks on th...
FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced un...
Gainers: Genius Brands International (NASDAQ: GNUS ) +73% . More news on: Genius Brands International, Inc., Cassava Sciences, Inc., Secoo Holding Limited, Stocks on the move, , Read more ...
Cellectar Biosciences (NASDAQ: CLRB ) has priced its public offering for gross proceeds of $20M. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Evofem Biosciences (NASDAQ: EVFM ) -26% after pricing equity offering. More news on: Evofem Biosciences, Inc., Cellectar Biosciences, Inc., Reinsurance Group of America, Incorporated, Stocks on the move, , Read more ...
FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten ...
FLORHAM PARK, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has been granted Small ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...